Skip to main content
Verona

Evotec takes on GSK site

Pharmaceutical CDMO Evotec has acquired GlaxoSmithKline’s site at Verona, Italy, where its Aptuit subsidiary is already active, employing 750. Terms were not disclosed. Following a meeting with site workers, the company has also agreed to rename the site Campus Levi-Montalcini, in honour of the Italian Nobel laureate Rita Levi-Montalcini.

The Hamburg-based company said that Campus Levi-Montalcini will be integral to its growth over the next few years, as planned under its global strategic framework, Action Plan 2025. The existing buildings and the site as a whole both offer potential for further capacity expansions.

“The site comprises all technologies and services needed to develop a drug discovery project from the idea, through pre-clinical and clinical development, all the way to the market,” Evotec added. These include, Indigo, the interdisciplinary service for accelerated drug development, API manufacturing, pre-formulation and cGMP drug product manufacture.

Add new comment

Plain text

  • No HTML tags allowed.
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.